Related Experiment Video
Updated: Oct 11, 2025
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.9K
Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis
Ping Zeng1, Meng Si1, Rui-Xia Sun2
1Department of Radiation Oncology, the First Affiliated Hospital of the USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Frontiers in Oncology
|December 6, 2021
Summary
Low CD9 expression indicates poor prognosis in solid tumors. This meta-analysis confirms CD9 as a valuable biomarker for predicting overall survival and time to progression in various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- Numerous studies have explored the link between CD9 expression and solid tumor prognosis, but findings remain inconclusive.
- CD9, a cell surface protein, is implicated in various cellular processes, including cell adhesion and migration, which are relevant to cancer progression.
Approach:
- A comprehensive meta-analysis was conducted, synthesizing data from 25 studies encompassing 5,555 participants.
- Statistical analysis, including hazard ratios and confidence intervals, was used to evaluate the prognostic significance of CD9 expression.
Key Points:
- Declined CD9 expression was significantly associated with poorer overall survival (OS) (HR = 1.88) and time to progression (TTP) (HR = 2.0) across solid tumors.
- Subgroup analyses indicated that low CD9 expression correlated with poor OS in lung and head and neck cancers, and poor TTP in head and neck cancer.
- The adverse prognostic impact of decreased CD9 expression was consistent across different ethnicities.
Conclusions:
- This meta-analysis provides robust evidence that reduced CD9 expression is a significant predictor of poor survival in human solid tumors.
- CD9 emerges as a potential prognostic biomarker and a therapeutic target for improving patient outcomes in solid tumor management.
